Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
P3-Fast · 1 trial · 1 indication
AUCinf
| Arm | Type | Description |
|---|---|---|
| Part A sequence 1 | EXPERIMENTAL | - |
| Part A sequence 2 | EXPERIMENTAL | - |
| Part B sequence 1 | EXPERIMENTAL | - |
| Part B sequence 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| P3-Fast | DRUG | 200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions |
| Comm-Fast | DRUG | 200 mg PF-04965842 commercial tablet formulation under fasted conditions |
| Vari-Fast | DRUG | 200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions |
| Comm-Fed | DRUG | 200 mg PF-04965842 commercial tablet formulation under fed conditions |
Inclusion Criteria: * Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb) Exclusion Criteria: * Any condition possibly affecting drug absorption (eg, gastrectomy). * History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis * Evidenc...
P3-Fast is an investigational small molecule being studied for atopic dermatitis, also known as eczema. It is being developed by Pfizer, Inc. as a potential treatment for this skin condition. The drug is currently in Phase 1 clinical development, meaning it is still being tested in early-stage trials to evaluate its safety and how it behaves in the body.
P3-Fast is being developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical research on this investigational small molecule for the treatment of atopic dermatitis, a form of eczema. The drug is currently in Phase 1 development.
P3-Fast is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 trial for P3-Fast has been completed, and the drug is being evaluated for its safety, tolerability, and pharmacokinetics in healthy volunteers.
P3-Fast has one completed clinical trial registered under the identifier NCT04065633. This Phase 1 study, titled "Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation," enrolled 46 participants in the United States. The trial was a controlled, randomized study that included healthy volunteers aged 18 years and older.
P3-Fast is associated with the compound PF-04965842, as indicated by the clinical trial title for NCT04065633. The trial evaluates formulations of PF-04965842, and P3-Fast appears to be a name used for this drug in the context of the study. The trial is a Phase 1 study conducted by Pfizer for atopic dermatitis.